March 19, 2009 - Digisonics will showcase their new DigiView Cath package with its imaging and reporting capabilites for the first time at the ACC 2009 meeting in Orlando, FL at booth #1773.

March 18, 2009 - Flexible Stenting Solutions Inc. (FSS) this week submitted an investigational device exemption (IDE) application to the FDA for its FlexStent Femoropopliteal SE Stent System for the treatment of peripheral artery disease in the superficial femoral and popliteal arteries.

March 18, 2009 - Cardiologists Edward Tadajweski, M.D., and Jeffrey L. Williams, M.D., MS, FACC, are the first in the U.S. to perform 3D imaging of complex cardiac anatomy using GE's Innova 3D imaging system.

March 18, 2009 - The U.S. Preventive Services Task Force (USPSTF) found that regular aspirin use reduces first heart attacks in men and first strokes in women and recommends daily aspirin use for certain patient populations.

March 18, 2009 - The success of Massachusetts hospitals and physicians to incorporate information technology (IT) into healthcare demonstrates the importance of incentives, according to two studies conducted by CSC and sponsored by Blue Cross Blue Shield of Massachusetts.

March 18, 2009 - GE said yesterday it was awarded two 10-year contracts by the Defense Supply Center Philadelphia (DSCP) to provide products for comprehensive patient monitoring solutions, including acute patient monitoring, networking, telemetry systems, vital signs monitoring.

Combined, these two contracts are valued at a maximum of $63 million annually.

March 18, 2009 – The American Heart Association (AHA) is urging Congress to accelerate its efforts to enact comprehensive healthcare reform and increase research funding to prevent setbacks in the fight against heart disease and stroke.

March 18, 2009 - Vicor Technologies Inc. has entered into a collaborative research agreement with the University of Rochester and the Catalan Institute of Cardiovascular Sciences in Barcelona to study sudden cardiac death.

March 17, 2009 – Twelve-month data from the ATLANTA Trial shows that the CATANIA Coronary Stent System with NanoThin Polyzene-F offers sustained benefit in the treatment of de novo coronary lesions and maximizes endothelialization, while reducing restenosis, thrombogenicity, and the need for long-term dual-antiplatelet therapy.

March 17, 2009 - Edwards Lifesciences Corp. announced it has completed enrollment in the 350-patient nonsurgical study arm of its PARTNER Trial for the Edwards SAPIEN transcatheter aortic heart valve.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now